The Egyptian Drug Authority (EDA) convened the third periodic meeting dedicated to the development of the Egyptian Pharmacopoeia. The meeting was chaired by Dr. Ayman El-Khatib, Vice President of the Egyptian Drug Authority and Chairman of the Permanent Committee for the Drafting of the Egyptian Pharmacopoeia, and was held at the Authority's headquarters in Agouza. 

During the meeting, participants agreed that the Egyptian Pharmacopoeia would be issued in an electronic format and made available through the official website of the Egyptian Drug Authority. It was further agreed that publication would be implemented in phases, with each section to be released following approval by the Permanent Committee for the Drafting of the Egyptian Pharmacopoeia and subsequent endorsement by the Authority's Board of Directors. 

The meeting also reviewed the composition of the working groups comprising representatives of the Egyptian Drug Authority from various disciplines, including human medicines, veterinary medicines, herbal products, hazardous and biological products, as well as active pharmaceutical ingredients and pharmaceutical raw materials. 

Proposed monograph templates were presented, and each working group submitted draft monographs within its respective area of specialization. It was agreed that all monographs would be prepared in the Common Technical Document (CTD) format to ensure consistency and alignment with internationally recognized regulatory practices. 

Dr. Ayman El-Khatib presented the proposed criteria for the selection of volunteers who would contribute to the preparation of the Egyptian Pharmacopoeia. In addition, Dr. Medhat El-Ghobashy indicated that the Egyptian Drug Authority would formally engage pharmaceutical companies to encourage the participation of qualified personnel in the development process. He further proposed extending invitations to relevant institutions to support the initiative through the nomination of volunteers and active participation. 

Dr. El-Khatib also emphasized the importance of establishing clear standards and eligibility requirements that would serve as the basis for selecting contributors and experts participating in the development of the Egyptian Pharmacopoeia.